The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 37 | — | 20.1x | Near average | |
Growth | 57 | 27.2% | 5.6% | Near average | |
Quality | 27 | -89.2% | 7.6% | Below average | |
Safety | 58 | 0.8x | 0.4x | Near average | |
Capital Return | 20 | 0.00% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Nurix Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Nurix Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Nurix Therapeutics stock shows remarkable stability in analyst estimates over the past 30 days, with the average price target holding steady at $31.83, representing a significant premium of over 80% compared to the current price ($17.5). The consensus of 10 analysts reflects sustained optimism, with a dispersion range between $28 and $36, indicating high confidence in the stock's intrinsic value despite the absence of recent valuation changes.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.